Compare AbCellera Biologics Inc (ABCL) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Raytheon Technologies Corp — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Raytheon Technologies Corp trades at $194.82 (market cap $270.48B). The key difference: Raytheon Technologies Corp is far larger — about 115.1× AbCellera Biologics Inc's market cap, and Raytheon Technologies Corp pays a 1.45% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | RTX | |
|---|---|---|
Market Cap | $2.35B | $270.48B |
Sector | Health | Industrials |
52-Week High | $8.12 | $212.16 |
52-Week Low | $2.78 | $144.91 |
Enterprise Value | $1.99B | $302.60B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
RTX trades at $201.37, up 1.06% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a $515 million Navy contract for SPY-6 radars highlight operational momentum. Revenue grew to $88.6 billion in 2025, with net income margin improving to 8.03%. The stock is near its consensus price target of $213, with no sell ratings among 26 analysts.
The outlook is positive, driven by defense contract wins and earnings growth, but risks include high valuation multiples and geopolitical dependencies. Upside potential exists if the company maintains its earnings beat streak and capitalizes on increased defense spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
